BlueSphere Bio

We’d like to thank our dedicated team for their passion, hard work and commitment to making BlueSphere an incredible place to work!

#ICYMI our CEO, Keir Loiacono, Esq., was featured in @biospace along with @UPMCEnterprises discussing what makes Pittsburgh a global life sciences hub, full of transformational technology, research and innovation. Check it out here: bit.ly/3g56XAW

Today, we announced the presentation of data that demonstrates the potential of our first and lead product candidate, BSB-1001, at this year’s 37th @sitcancer annual meeting. Learn more here: bit.ly/3hxKmNR #SITC2022

Our Chief Development Officer, Robert Keefe, Ph.D., is presenting data in a poster at this year’s 37th @sitcancer annual meeting. Learn more here: bit.ly/3UkFjOL

#ICYMI our team participated in The Leukemia & Lymphoma Society #LightTheNight walk and raised over $5K to support @LLSusa We’d like to thank our team for their support and dedication.

#ICYMI we appointed Keir Loiacono, Esq. Chief Executive Officer of BlueSphere Bio. Learn more about how Keir plans to advance our first candidate to the clinic next year in this @biospace article: bit.ly/3CCtyx5

Today, we’re pleased to announce that Keir Loiacono, Esq., has been appointed Chief Executive Officer of BlueSphere Bio. Learn more here: bit.ly/3CxMmNW

#ICYMI we presented preclinical data supporting the ability of our TCXpress™ and iTCXpress™ platforms to rapidly and efficiently identify novel TCR candidates at the 7th annual CAR-TCR Summit. Check out our team in action below and learn more here: bit.ly/3Sp62tb

Today, we announced the presentation of preclinical data supporting the ability of our TCXpress™ and iTCXpress™ platforms to rapidly and efficiently identify novel TCR candidates, at the 7th annual CAR-TCR Summit. Learn more about the data here: bit.ly/3LRNnnd

At this year’s 7th Annual CAR-TCR Summit being held in Boston, MA from September 19 – 22, we’re presenting a poster highlighting our TCXpress™ and iTCXpress™ platforms. For more information, click here: bit.ly/3LrDPPE

At BlueSphere Bio, we’re expanding our team of talented individuals who share our passion for creating novel #CellTherapies for treating #cancer. Check out our current openings here: bit.ly/3prj3Xd #JobOpenings #Hiring

Our proprietary, high-throughput & efficient TCR capture, expression, and functional screening platform, TCXpress™ is capable of processing 1000s of single T cells directly into functionally expressed TCRs within a matter of days. Learn more here: bit.ly/3x4N1Uj

Our programs are designed to unlock the potential of TCR T-cell therapies for the treatment of both #HematologicalMalignancies and #SolidTumors. Learn more about our programs in development here: bit.ly/3u6W99g

We’re proud to have our headquarters located in the heart of Pittsburgh, a thriving health technology hub. Learn more about our great city here: bit.ly/3z5UXEP

At BlueSphere Bio, our mission is to create TCR T-cell therapies that harness the immune response of patients to cure #cancer. Every cancer is unique and so are our #CellTherapies in development. Learn more about our approach here: bit.ly/3krHW1w

Check out these #interviews from @VJHemOnc featuring our CEO, David Apelian, M.D., Ph.D., MBA, where he discusses our TCXpress™ platform. Watch here: bit.ly/3IFxRZS

At BlueSphere Bio, we’re expanding our team of talented individuals who share our passion for creating novel #CellTherapies for treating #cancer. Check out our current openings here: bit.ly/3prj3Xd #JobOpenings #Hiring

#ICYMI our team attended the 2022 Pittsburgh Pride Revolution parade. At BlueSphere Bio, we continue to show our support for diversity and inclusion. Check out our team below! #PrideMonth

Our Co-Founder & CSO, Mark Shlomchik, M.D., Ph.D., sat down with @pharmasalmanac to discuss BlueSphere’s platform technologies, which are designed to rapidly develop effective personalized TCR T cell therapies for the treatment of solid tumors. Read here: bit.ly/3mgJ3lF